Angela Y. Moore M.D.

Moore, A.Y., Nguyen, M. and Moore, S. (2021). “Cyclic calcipotriene 0.005% foam and 1% 5-fluorouracil cream after cryotherapy in treatment of hyperkeratotic actinic keratosis: A retrospective study.” J Am Acad Dermatol 84(4): 1148-1150.

Full text of this article.

Traditional treatments for actinic keratoses include cryotherapy, 5-fluorouracil cream, imiquimod, diclofenac, ingenol mebutate gel, and photodynamic therapy.1,2 Recent research suggests topical vitamin D3 as possibly efficacious by mounting a robust antitumor immunoresponse via T-cell recruitment.3 We hypothesized that these treatments may be synergistic and that vitamin D3 would enhance the efficacy of 5-fluorouracil cream in hyperkeratotic actinic keratoses treatment after cryotherapy. [No abstract; excerpt from article]

Moore, A.Y., Del Rosso, J., Johnson, J.L. and Grada, A. (2020). “Sarecycline: A Review of Preclinical and Clinical Evidence.” Clin Cosmet Investig Dermatol 13: 553-560.

Full text of this article.

Sarecycline is a tetracycline-derived oral antibiotic, specifically designed for acne, and is approved by the Food and Drug Administration (FDA) in 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris (AV) in patients 9 years of age and older. It has been decades since a novel systemic antibiotic was approved to treat AV, a disease that affects up to 90% of teenagers and young adults worldwide and lasts well into adulthood. Sarecycline holds promise to yield fewer side effects than other commonly used broad-spectrum tetracyclines, including minocycline and doxycycline. The narrower spectrum of antibacterial activity of sarecycline, which specifically targets C. acnes and some Gram-positive bacteria with little or no activity against Gram-negative bacteria, suggests not only the potential for reduced emergence of antibiotic-resistant bacterial strains but also less disruption of the human gut microflora. Here, we review the key preclinical and clinical evidence on sarecycline.

Moore, A. Y., M. Nguyen and S. Moore (2020). “Cyclical Calcipotriene 0.005% Foam and 1% 5-Fluorouracil Cream After Cryotherapy in Treatment of Hyperkeratotic Actinic Keratosis: A Retrospective Study.” J Am Acad Dermatol Jul 8;S0190-9622(20)32174-5. [Epub ahead of print.].

Full text of this article.

Raoof, T. J., D. Hooper, A. Moore, M. Zaiac, T. Sullivan, L. Kircik, E. Lain, J. Jankicevic and I. Stuart (2020). “Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study.” J Am Acad Dermatol 82(4): 832-837.

Full text of this article.

BACKGROUND: FMX101 4% topical minocycline foam has been shown to be an effective and safe treatment for acne vulgaris (AV). OBJECTIVE: To further evaluate the efficacy and safety of FMX101 4% in treating moderate to severe acne vulgaris. METHODS: A 12-week, multicenter, randomized (1:1), double-blind, vehicle-controlled study was conducted. Coprimary end points were the absolute change in inflammatory lesion count from baseline and the rate of treatment success (Investigator’s Global Assessment score of 0 or 1 with a >/=2-grade improvement). RESULTS: There were 1488 participants in the intent-to-treat population. The FMX101 4% group had significantly greater reductions in the number of inflammatory lesions from baseline (P < .0001) and a greater rate of treatment success based on Investigator's Global Assessment (P < .0001) versus the foam vehicle group at week 12. FMX101 4% was generally safe and well tolerated. LIMITATIONS: The efficacy and safety of FMX101 4% were not characterized in participants with mild AV. CONCLUSION: FMX101 4% topical minocycline.

Moore, A. Y., J. E. M. Charles and S. Moore (2019). “Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris.” Future Microbiol Sep 2. [Epub ahead of print].

Full text of this article.

Sarecycline is a novel, narrow-spectrum, once-daily tetracycline-derived oral antibiotic that is FDA-approved in the US to be taken with or without food for moderate-to-severe acne vulgaris for ages 9 years of age and older. Sarecycline possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of Cutibacterium acnes, while exhibiting minimal activity against enteric aerobic Gram-negative bacteria. Unlike many acne studies, sarecycline was investigated for chest and back acne. Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3. No reports of phototoxicity, dizziness, pseudotumor cerebri or lupus but 1.2% nausea and 1.2% vaginal candidiasis was reported in the pivotal Phase III studies.